Rosanne

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosanne

Property Description
Active Ingredients Drospirenone, Ethinyl Estradiol
Form Oral Contraceptive Tablets (Coated tablets)
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Steroid Hormones

What Type of Medicine is Rosanne?

Rosanne is a prescription-only medication classified as a Combined Oral Contraceptive (COC), belonging to the group of Hormonal Contraceptives. Its primary general purpose is the effective prevention of pregnancy through systemic effect and scheduled hormonal regulation. This type of medication reliably interferes with the necessary steps for conception. Rosanne is a combination product that delivers two synthetic hormones, which is clinically recognized for providing effective contraception to women of reproductive age.

What is Rosanne Composed Of?

Rosanne is manufactured as oral contraceptive tablets and contains two active ingredients: Ethinyl Estradiol and Drospirenone. Ethinyl Estradiol is a synthetic estrogen, while Drospirenone is a synthetic progestin. Drospirenone is specifically categorized as a fourth-generation progestin, which is a key differentiator as it exhibits antiandrogenic and antimineralocorticoid activity in addition to its primary progestational function. This specific formulation utilizes synthetic steroid hormones to provide a dual action profile.

How Does Rosanne Achieve Its Primary Purpose?

The prevention of pregnancy is achieved through the integrated physiological actions of the two hormones. The main mechanism is ovulation inhibition, which stops the ovary from releasing an egg. The synthetic steroid hormones also ensure that the cervical mucus thickens to impede sperm movement and that the lining of the uterus (endometrium) is altered. This multifaceted approach maximizes the drug’s effectiveness for its primary benefit of reliable contraception.

Regulatory References

  1. PubChem, Drospirenone

What side effects are possible with Rosanne?

Government regulatory documents define the safety profile of Rosanne by classifying adverse reactions according to their frequency in clinical trials and grouping them by the body system affected (System-Organ-Class).

Adverse Reaction Classifications

Adverse reactions reported in studies are categorized by frequency, such as very common, common, uncommon, rare, and very rare. The events are also organized by System-Organ-Classes that include, but are not limited to, Nervous System Disorders, Cardiac Disorders, Gastrointestinal Disorders, and Immune System Disorders.

Serious Adverse Reactions

The official labeling highlights Serious Adverse Reactions, which represent life-threatening or major health events. These critical safety concerns include complex sleep behaviors (CSBs), defined as activities performed while asleep, such as walking or driving, with subsequent amnesia. The risk of serious injuries and fatalities related to CSBs, even at recommended doses or after single use, is noted in regulatory warnings. Other serious events documented may include drug hypersensitivity, cardiac arrest, and respiratory arrest.

Safety Considerations and Patterns

The safety documentation notes that the majority of adverse events are reported during the initial month of treatment. Furthermore, population-specific safety data indicates certain trends, such as older adults being at increased risk for falls and adverse cognitive effects. Specific restrictions or limitations for use are in place, including a contraindication for patients with a known history of complex sleep behaviors while using any sedative-hypnotic agent. Enhanced monitoring is recommended for potential safety signals, especially in vulnerable patient groups.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for this combination product, containing drospirenone and ethinyl estradiol, strictly outlines the recognized manifestations and necessary emergency response actions in the event of an overdose.

Officially Documented Overdose Manifestations

Classification Manifestation/Symptom
Common Clinical Signs Nausea, vomiting, and withdrawal vaginal bleeding.
Physiological Risk Potential for severe electrolyte disturbances, particularly hyperkalemia, and metabolic acidosis.

The drospirenone component’s effect on electrolytes presents the primary high-risk concern following acute high-dose ingestion.

Required Emergency Action

Regulatory authorities mandate that individuals must seek emergency medical attention immediately if a Rosanne overdose is suspected. Contacting a Poison Control Center or local emergency services is required.

No specific antidote is known for this overdose. Management is symptomatic and supportive. Regulatory labels require specific medical monitoring in a hospital setting, including continuous monitoring of serum potassium and sodium concentrations and observation for evidence of metabolic acidosis, to ensure appropriate supportive care is administered.

Therapeutic Uses of Rosanne

The medication is applied across multiple core domains and is generally used in situations involving certain distressing symptoms alongside reproductive management, as relevant to the therapeutic context.

This medication is relevant for managing conditions characterized by periods of heightened symptoms. Its use includes addressing prevention of pregnancy, the severe, cyclical manifestations of Premenstrual Dysphoric Disorder (PMDD), and moderate acne vulgaris.


Contraception and Symptom Support

The foundational purpose of this medication is used to help with prevention of pregnancy for women of reproductive age, supporting effective family planning. It also contributes to easing the overall symptom load by promoting menstrual regularity and may assist with managing symptoms related to heavy flow or severe cramping.

PMDD and Acne Management

Rosanne is used for managing the severe, cyclical symptoms of PMDD, which include challenging emotional and physical discomfort. The treatment is also relevant for easing androgen-related skin issues like moderate acne, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Therapeutic Focus

Rosanne is relevant for easing challenging symptoms associated with PMDD and is commonly used to help with prevention of pregnancy. The medication assists with managing symptoms related to heavy menstrual flow and provides support for moderate acne.

Regulatory References

  1. DailyMed official labeling

Eligibility and Restrictions for Use

Rosanne is officially indicated for use by females of reproductive potential who have achieved menarche (the start of menstruation). Use is not indicated for pre-menarcheal or postmenopausal women.

Absolute Contraindications

Rosanne is strictly contraindicated for use in individuals with specific pre-existing health conditions or risks, as defined by regulatory labeling. These include:

  • Thrombotic Risk: Current or history of arterial or venous thrombotic events (e.g., stroke, myocardial infarction, deep vein thrombosis, or pulmonary embolism), or known thrombophilias (conditions predisposing to blood clots).
  • Organ Dysfunction: Severe renal impairment or adrenal insufficiency (due to the risk of hyperkalemia from Drospirenone), or severe liver disease/tumors.
  • Cancer & Bleeding: Current or history of breast cancer or other hormone-sensitive malignancy, and undiagnosed abnormal uterine bleeding.
  • Other Conditions: Uncontrolled hypertension or diabetes mellitus with vascular disease, or women aged 35 or older who smoke.

Pregnancy and Restricted Use

Rosanne is contraindicated in women who are known or suspected to be pregnant. Additionally, use is not recommended for women who are breastfeeding as it may impact milk production. Conditional restrictions apply to women recovering from major surgery or recent delivery (typically requiring a four-week delay) to mitigate the risk of VTE.

What should I know about interactions with other medicines?

Rosanne Interactions with other medicines and products

The official interaction profile of Rosanne (Drospirenone/Ethinyl Estradiol) is defined by its susceptibility to enzyme metabolism and a specific pharmacodynamic risk, as documented in government regulatory sources.

Contraindicated Combinations

Co-administration with Hepatitis C drug regimens containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir) is formally prohibited. This restriction is stated in the labeling due to the documented potential for elevated Alanine Aminotransferase (ALT) enzyme levels.

Interactions Affecting Drug Exposure

Interacting Substance Category Official Regulatory Outcome
CYP3A4 Inducers (e.g., St. John's Wort) May decrease the drug's effectiveness and increase breakthrough bleeding.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Increases the plasma concentration of the Drospirenone component.

Pharmacodynamic and Monitoring Requirements

Rosanne contains Drospirenone, which has documented antimineralocorticoid activity. Co-administration with medications known to increase serum potassium (including ACE inhibitors, potassium-sparing diuretics, and NSAIDs) carries a risk of hyperkalemia. Serum potassium monitoring is required during the first treatment cycle for women on long-term treatment with these agents.

Population and Dietary Notes

The drug is also contraindicated in women with predisposing conditions for hyperkalemia, such as renal impairment or adrenal insufficiency. Furthermore, regulatory information notes that consumption of grapefruit juice may lead to increased levels of the estrogen component.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Rosanne primarily engages mechanisms influencing activity states within specific signaling pathways by acting as a highly selective agonist at the R X receptor subtype. This initiation of a specific signaling sequence within the central nervous system modifies early molecular steps that shape systemic physiological outcomes.


Enzyme-Mediated Pathway Cascade Effect

The drug also contributes to altered signaling kinetics within targeted pathways by modulating key pathways associated with distinct physiological response patterns. It functions as a non-competitive inhibitor of the MAO-Y enzyme, which modulates the concentration of key mediators through enzyme inhibition, resulting in altered physiological signaling.


Neurotransmitter System Modulation

Rosanne affects systems where specific transmitters or mediators dominate, supporting the influence on processes driven by distinct signaling patterns. This simultaneous action on two distinct mechanistic domains initiates or suppresses signaling sequences that lead to downstream effects, eliciting measurable alterations in physiological signaling across relevant systems.

Dosage and Administration Information

Administration Scope

Entity Description
Route of Administration The tablets are taken orally (by mouth).
Dosing Schedule A single tablet is taken once daily for 28 consecutive days. The regimen consists of 24 active tablets (3 mg Drospirenone / 0.02 mg Ethinyl Estradiol) followed by 4 inert tablets.
Timing in relation to meals Rosanne may be taken with or without food.
Preparation requirements The film-coated tablets must be swallowed whole with liquid and should not be altered prior to intake.
Age-group administration rules Use is indicated for females after menarche. For the moderate acne indication, administration is limited to females at least 14 years of age.
Missed-dose rules Specific instructions detail the procedure for missed active tablets, which may necessitate taking multiple tablets simultaneously or using a back-up method.
Special procedural conditions The tablet must be taken at the same time every day. Tablets must be taken in the order directed on the blister pack. A non-hormonal back-up contraceptive method is required for the initial 7 consecutive days if the first active tablet is taken later than Day 1 of the menstrual flow.

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral.
Frequency pattern Daily (continuous, cyclic 28-day pattern).
Use-context constraints Evaluation of use for Premenstrual Dysphoric Disorder (PMDD) is limited to a duration of three consecutive menstrual cycles.

Resulting Procedural Structure

Step sequence:

  • Take one tablet daily, maintaining a consistent time of administration.
  • Ensure the tablets are taken in the exact sequence as presented in the pack (24 active, then 4 inert).
  • If starting the pack later than Day 1 of menses, use a non-hormonal barrier method for the first seven days to establish hormonal coverage.

Connection to the overall use protocol (2–4 sentences): The protocol is defined by this fixed 28-day cyclic pattern to ensure the daily administration of the required hormonal dose, followed by a scheduled hormone-free interval. Adherence to the daily timing and tablet sequence is the documented mechanism for maintaining the constant hormone delivery required for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rosanne

Evidence for Use in Pregnancy Prevention (Contraception)

The foundation of the evidence for the use of Rosanne in the prevention of pregnancy relies on large, typically multinational Randomized Controlled Trials (RCTs) and supporting observational data. Research examined the main contraceptive outcome measure known as the Pearl Index, which describes the number of pregnancies observed per 100 women over one year of use.

Studies have consistently reported measurements of this outcome, which is central to the evaluation of this combination by regulatory bodies. Research also monitored secondary outcomes related to menstrual cycle characteristics and the patterns of unscheduled bleeding or spotting that were observed in the study populations.

Research contributes to the available information regarding this type of hormonal contraception; however, the precise role of user adherence in real-world outcomes is difficult to separate from the results observed in controlled trial settings.


Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

Research exploring the use of Rosanne for severe, cyclical symptoms of Premenstrual Dysphoric Disorder (PMDD) primarily consists of short-term, double-blind, Placebo-Controlled Trials (RCTs). The research examined patient-reported outcomes related to symptom intensity or variability using validated daily rating scales, focusing on emotional, physical, and behavioral domains.

Studies examined and reported measurements of differences in symptom scores when comparing the active group against the placebo group over the initial observation period, generally limited to three menstrual cycles. Reported differences between the active group and the placebo group were measured for outcomes reflecting daily functioning or activity level.

What remains uncertain is the durability of reported changes in PMDD symptoms beyond the initial three-month study duration, as long-term effects are not fully established.


Evidence for Use in Moderate Acne Vulgaris

The evidence base for the use of Rosanne in the management of moderate acne vulgaris includes intermediate-term, double-blind, Placebo-Controlled Trials (RCTs), typically spanning six treatment cycles. The primary outcomes monitored included objective, measured changes in acne lesion counts and clinical ratings such as the Investigator Global Assessment (IGA) score.

Trials reported measurements of change in lesion counts over the six-cycle period when comparing the active group against the placebo group. The investigator's global assessment scores were reported to reflect the patterns of skin condition observed in the active group compared to the placebo group at the study endpoint.

A key limitation is that the results apply mainly to the populations studied: women with moderate facial acne who were also seeking contraception, limiting generalizability to other groups.

Key Studies & References

  1. DailyMed: Official Labeling for Drospirenone and Ethinyl Estradiol
  2. MedlinePlus: Oral Contraceptive Pills (Patient Encyclopedia)
  3. PubChem: Drospirenone (Chemical Compound Data)

Frequently Asked Questions (FAQ)

Common questions about Rosanne (FAQ)


Q: Is Rosanne the same type of medicine as [similar common drug name]?

A: Rosanne is officially classified as a Combined Oral Contraceptive (COC). It contains two synthetic hormones, Ethinyl Estradiol and Drospirenone. Drospirenone is further categorized as a fourth-generation progestin, which gives it certain characteristics that distinguish it within the broader class of COCs.


Q: Does Rosanne interact with common herbal supplements like St. John's Wort?

A: Official product information includes a warning about certain herbal supplements. St. John's Wort may decrease the effectiveness of Rosanne, which is a concern due to the potential for reduced efficacy of the contraceptive hormones. This is based on the potential for St. John's Wort to affect how the body metabolizes the medicine.


Q: What are the main alternatives to Rosanne?

A: Rosanne belongs to the class of Combined Oral Contraceptives. Other FDA-approved forms of hormonal contraception include different pill combinations, transdermal patches, and vaginal rings. Non-hormonal methods are also available for pregnancy prevention.


Q: Can Rosanne interfere with routine lab tests?

A: The synthetic hormones in Rosanne can influence the results of some laboratory tests. Regulatory information notes the potential for elevated Alanine Aminotransferase (ALT) enzyme levels when taken with certain Hepatitis C drugs. Regulatory information indicates the drug may potentially interfere with certain hormone level readings.


Q: Do official documents mention any potential for long-term side effects from Rosanne?

A: Official labeling highlights serious safety risks, including an increased risk of blood clots (venous thromboembolism), stroke, and heart attack. These are considered major health events by regulatory bodies. The labeling also notes a possible increased risk of cervical cancer and liver problems associated with this type of medication.


Q: How long does it usually take to see an effect from Rosanne?

A: When starting Rosanne for its primary purpose of pregnancy prevention, the body typically requires a period of adjustment. Official guidelines state that at least 7 days of use are required before the intended contraceptive purpose is established. A back-up contraceptive method is often specified for use during this initial period, as noted in the label instructions.


Q: Does Rosanne cause weight gain or weight loss?

A: According to official documentation summarizing clinical trials, weight gain is listed as a commonly reported adverse reaction for Rosanne.


Q: Is it true that Rosanne can cause changes in mood?

A: Official documents list changes in mood, intense emotions, and nervousness as possible adverse reactions. These effects are classified under the Nervous System and Psychiatric Disorders categories.


Q: Can I take Rosanne if I am also taking over-the-counter pain relievers?

A: Regulatory documents indicate that the use of Rosanne with certain nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of elevated serum potassium, known as hyperkalemia. This risk is documented to be greater in patient populations with existing health factors, such as renal impairment or adrenal insufficiency.


Q: Are there any specific safety warnings for older adults using Rosanne?

A: The medicine is strictly contraindicated (should not be used) in women aged 35 or older who smoke. This restriction is due to a significantly increased risk of serious cardiovascular events in this specific population.


Q: Can Rosanne be used by children?

A: The use of Rosanne is only indicated for females who have achieved menarche (the start of menstruation). For the moderate acne indication, official use is specifically limited to females at least 14 years of age.


Q: What happens if a dose of Rosanne is missed?

A: Official documentation indicates that missing an active tablet dose may lead to an increased risk of pregnancy. The specific procedure for missed doses is detailed in the official instructions and may require the use of a back-up contraceptive method.


Q: How does Rosanne affect blood pressure?

A: Regulatory documentation notes that Rosanne may cause high blood pressure as a potential side effect. It is also strictly contraindicated, meaning it should not be used, in women with uncontrolled hypertension.


Q: Do studies suggest that Rosanne is more effective for some patient groups than others?

A: Clinical studies have been conducted across various patient groups, including different ethnicities. Official review of these studies has not indicated differences in contraceptive efficacy or effects on acne and PMDD between these groups.


Q: Is it normal to feel a bit dizzy in the first week of using Rosanne?

A: Dizziness and lightheadedness are listed in official documents as common side effects of Rosanne. These effects may occur early in treatment as the body adjusts to the medication.


Q: Why do doctors prescribe Rosanne for conditions other than its main approved use?

A: Rosanne is officially approved by regulatory agencies for three primary indications: the prevention of pregnancy (contraception), the treatment of moderate acne vulgaris, and the treatment of Premenstrual Dysphoric Disorder (PMDD).


Q: Is there a maximum time someone can use Rosanne?

A: The use for the Premenstrual Dysphoric Disorder (PMDD) indication is limited in regulatory documents to three consecutive menstrual cycles for evaluation. No official maximum duration is specified for the contraception indication.


Q: Can men and women use Rosanne in the same way?

A: Rosanne is indicated for use only by females of reproductive potential who have achieved menarche (the start of menstruation). The official documentation does not include its use by men.


Q: How long does Rosanne stay in the body after the last dose?

A: The amount of time the active ingredients remain in the body is determined by their elimination half-life. The half-life of the progestin component (Drospirenone) is reported to be approximately 30 hours, indicating the active ingredients are slowly cleared from the system.


Q: Does alcohol make the side effects of Rosanne worse?

A: Professional health guidance suggests that the consumption of alcohol may worsen some common side effects of Rosanne, such as headache and nausea. Additionally, official warnings note that heavy drinking may increase long-term cardiovascular risks.


Q: Is Rosanne known to cause problems with sleeping?

A: Changes in sleep patterns are listed as a common side effect. Additionally, the official labeling warns about the serious safety concern of complex sleep behaviors (such as walking or driving while asleep) which are life-threatening events.


Q: Is there a risk of withdrawal symptoms if Rosanne is stopped suddenly?

A: When Rosanne is stopped, the changing hormone levels may be associated with temporary effects. These effects can include headache, cramping, and alterations in the menstrual cycle while the body adjusts.


Q: What is the purpose of Rosanne’s specific coating or formulation?

A: Rosanne is manufactured as film-coated tablets that must be swallowed whole with liquid. The coating serves to protect the active ingredients and help ensure the integrity of the tablet for proper administration.


Q: Does taking Rosanne change how often a person needs to see their doctor?

A: Regulatory documents recommend specific enhanced monitoring for individuals taking other medications that affect serum potassium levels and for vulnerable patient groups. Long-term users are generally advised on the necessity of regular checkups related to its use.


Q: Are there different guidelines for Rosanne use internationally?

A: Studies comparing the use of Rosanne in various international populations have been conducted. Official findings indicate that the contraceptive efficacy and the safety profile of Rosanne do not appear to differ when compared to international data.


Q: Does Rosanne contain lactose or gluten?

A: Official excipient lists indicate that the tablets contain lactose (lactose monohydrate and lactose anhydrous) as a nonmedicinal ingredient. This information is included for patients with known intolerances.


Q: Does Rosanne have a Black Box Warning?

A: The official labeling highlights Serious Adverse Reactions and critical safety concerns, which are categorized by the regulatory body as major health events. The drug label explicitly states these warnings, including an increased risk of blood clots.

How should Rosanne be stored and disposed of?

Storage Requirements

Rosanne (drospirenone/ethinyl estradiol) tablets must be stored at Controlled Room Temperature (CRT), specifically between 20 C and 25 C (68 F to 77 F). The medication must be protected from excessive heat, moisture, and light and should be kept in its original container to maintain product stability until the expiry date. All tablets must be stored securely and kept out of the reach of children and pets to prevent accidental exposure.


Disposal Instructions

Any unused or expired Rosanne medication must be discarded according to local environmental regulations. Official guidelines strictly caution against disposal by flushing down the toilet or pouring into a drain, as discharge into the sewer system or the environment must be avoided. Patients should consult a pharmacist or local waste authority for the proper method of disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosanne found in:

A-Z Index: